US3465044A - 2,4- and 2,6-dihalobenzyl methyl sulfoxides and sulfones - Google Patents
2,4- and 2,6-dihalobenzyl methyl sulfoxides and sulfones Download PDFInfo
- Publication number
- US3465044A US3465044A US619167A US3465044DA US3465044A US 3465044 A US3465044 A US 3465044A US 619167 A US619167 A US 619167A US 3465044D A US3465044D A US 3465044DA US 3465044 A US3465044 A US 3465044A
- Authority
- US
- United States
- Prior art keywords
- solution
- methyl
- added
- water
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000003457 sulfones Chemical class 0.000 title description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical class CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 title description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 52
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 39
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 37
- 239000000243 solution Substances 0.000 description 36
- 239000000203 mixture Substances 0.000 description 31
- 150000001875 compounds Chemical class 0.000 description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- -1 triamcinoline Chemical compound 0.000 description 23
- 238000006243 chemical reaction Methods 0.000 description 22
- 239000002904 solvent Substances 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 239000007864 aqueous solution Substances 0.000 description 16
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 16
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 16
- 238000001704 evaporation Methods 0.000 description 14
- 230000008020 evaporation Effects 0.000 description 14
- 230000008018 melting Effects 0.000 description 14
- 238000002844 melting Methods 0.000 description 14
- 239000013078 crystal Substances 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- 238000001816 cooling Methods 0.000 description 10
- 229920006395 saturated elastomer Polymers 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000007800 oxidant agent Substances 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 239000002260 anti-inflammatory agent Substances 0.000 description 8
- 229940121363 anti-inflammatory agent Drugs 0.000 description 8
- 235000010265 sodium sulphite Nutrition 0.000 description 8
- 150000003462 sulfoxides Chemical class 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- YQGFLUVOLNGRET-UHFFFAOYSA-N 1,3-dichloro-2-(methylsulfonylmethyl)benzene Chemical compound CS(=O)(=O)CC1=C(Cl)C=CC=C1Cl YQGFLUVOLNGRET-UHFFFAOYSA-N 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- LYPGDCWPTHTUDO-UHFFFAOYSA-M sodium;methanesulfinate Chemical compound [Na+].CS([O-])=O LYPGDCWPTHTUDO-UHFFFAOYSA-M 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000004821 distillation Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- DOUJWULDOHKAQB-UHFFFAOYSA-N 1,3-dichloro-2-(methylsulfanylmethyl)benzene Chemical compound CSCC1=C(Cl)C=CC=C1Cl DOUJWULDOHKAQB-UHFFFAOYSA-N 0.000 description 3
- GURSJEKDEDOYNT-UHFFFAOYSA-N 2,4-dichloro-1-(methylsulfanylmethyl)benzene Chemical compound CSCC1=CC=C(Cl)C=C1Cl GURSJEKDEDOYNT-UHFFFAOYSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- FRIBMENBGGCKPD-UHFFFAOYSA-N 3-(2,3-dimethoxyphenyl)prop-2-enal Chemical compound COC1=CC=CC(C=CC=O)=C1OC FRIBMENBGGCKPD-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical class CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- BRRWQLFHAQOABB-UHFFFAOYSA-N 1-chloro-3-fluoro-2-(methylsulfanylmethyl)benzene Chemical compound CSCC1=C(F)C=CC=C1Cl BRRWQLFHAQOABB-UHFFFAOYSA-N 0.000 description 2
- NLOQSEABGFEYDE-UHFFFAOYSA-N 2,4-dichloro-1-(methylsulfonylmethyl)benzene Chemical compound CS(=O)(=O)CC1=CC=C(Cl)C=C1Cl NLOQSEABGFEYDE-UHFFFAOYSA-N 0.000 description 2
- YNJSNEKCXVFDKW-UHFFFAOYSA-N 3-(5-amino-1h-indol-3-yl)-2-azaniumylpropanoate Chemical compound C1=C(N)C=C2C(CC(N)C(O)=O)=CNC2=C1 YNJSNEKCXVFDKW-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- ZWWCURLKEXEFQT-UHFFFAOYSA-N dinitrogen pentaoxide Chemical compound [O-][N+](=O)O[N+]([O-])=O ZWWCURLKEXEFQT-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229960002895 phenylbutazone Drugs 0.000 description 2
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 2
- 239000012286 potassium permanganate Substances 0.000 description 2
- 239000011369 resultant mixture Substances 0.000 description 2
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- LBOBESSDSGODDD-UHFFFAOYSA-N 1,3-dichloro-2-(chloromethyl)benzene Chemical compound ClCC1=C(Cl)C=CC=C1Cl LBOBESSDSGODDD-UHFFFAOYSA-N 0.000 description 1
- AHZWBOMWAKYLIS-UHFFFAOYSA-N 1-bromo-2-(bromomethyl)-3-chlorobenzene Chemical compound ClC1=CC=CC(Br)=C1CBr AHZWBOMWAKYLIS-UHFFFAOYSA-N 0.000 description 1
- IRSVDHPYXFLLDS-UHFFFAOYSA-N 2,4-dichloro-1-(chloromethyl)benzene Chemical compound ClCC1=CC=C(Cl)C=C1Cl IRSVDHPYXFLLDS-UHFFFAOYSA-N 0.000 description 1
- PDFGFQUSSYSWNI-UHFFFAOYSA-N 2-(bromomethyl)-1,3-dichlorobenzene Chemical compound ClC1=CC=CC(Cl)=C1CBr PDFGFQUSSYSWNI-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- RMMXTBMQSGEXHJ-UHFFFAOYSA-N Aminophenazone Chemical compound O=C1C(N(C)C)=C(C)N(C)N1C1=CC=CC=C1 RMMXTBMQSGEXHJ-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 231100000111 LD50 Toxicity 0.000 description 1
- 208000023178 Musculoskeletal disease Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- AYTHAXUMFKBTSN-UHFFFAOYSA-N [NH4+].CS([O-])=O Chemical compound [NH4+].CS([O-])=O AYTHAXUMFKBTSN-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229960000212 aminophenazone Drugs 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 210000004198 anterior pituitary gland Anatomy 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- KRVSOGSZCMJSLX-UHFFFAOYSA-L chromic acid Substances O[Cr](O)(=O)=O KRVSOGSZCMJSLX-UHFFFAOYSA-L 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- AWJWCTOOIBYHON-UHFFFAOYSA-N furo[3,4-b]pyrazine-5,7-dione Chemical compound C1=CN=C2C(=O)OC(=O)C2=N1 AWJWCTOOIBYHON-UHFFFAOYSA-N 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000004966 inorganic peroxy acids Chemical class 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- JYJVVHFRSFVEJM-UHFFFAOYSA-N iodosobenzene Chemical compound O=IC1=CC=CC=C1 JYJVVHFRSFVEJM-UHFFFAOYSA-N 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- ACKFDYCQCBEDNU-UHFFFAOYSA-J lead(2+);tetraacetate Chemical compound [Pb+2].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O ACKFDYCQCBEDNU-UHFFFAOYSA-J 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229940042126 oral powder Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000004967 organic peroxy acids Chemical class 0.000 description 1
- 229960000649 oxyphenbutazone Drugs 0.000 description 1
- HFHZKZSRXITVMK-UHFFFAOYSA-N oxyphenbutazone Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 HFHZKZSRXITVMK-UHFFFAOYSA-N 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 150000004968 peroxymonosulfuric acids Chemical class 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 150000003218 pyrazolidines Chemical class 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229910001927 ruthenium tetroxide Inorganic materials 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical class OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- BAZAXWOYCMUHIX-UHFFFAOYSA-M sodium perchlorate Chemical compound [Na+].[O-]Cl(=O)(=O)=O BAZAXWOYCMUHIX-UHFFFAOYSA-M 0.000 description 1
- 229910001488 sodium perchlorate Inorganic materials 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 125000005424 tosyloxy group Chemical group S(=O)(=O)(C1=CC=C(C)C=C1)O* 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/02—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms
- C07C317/10—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
Definitions
- Inflammation in its various manifestations represents one of the serious problems in the clinical field. Although it is known that many diseases may be engendered thereby,
- Present anti-inflammatory agents can be divided into two groups; (a) steroidal anti-inflammatory agents, re.
- adrenocortical hormones such as prednisolone, triamcinoline, hydrocortisone, dexamethasone, or the like
- non-steroidal anti-inflammatory agents which consist mainly of pyrazolidine derivatives such as phenylbutazone, oxyphenbutazone, 1,4-diphenyl-3,S-dioxopyrazolidine, aminopyrine, and the like, salicyclic acid derivatives such as acetyl salicyclic acid, and the like, andmore recentlydimethylsulfoxide.
- Anti-inflammatory action 1 Dose, Inhibition, Probability, LD Compound mg./k. percent percent mgJkg.
- the median lethal dose (LD;,0) was measured by intraperitoneal administration in m ce.
- These compounds (I) can be prepared by, for example, subjecting the compounds of the formula I @om-s-om wherein X has the same meaning as above, to oxidation.
- such conventional oxidizing agents may be employed as, for example, hydrogen peroxide, manganese dioxide, nitric acid, chromic acid, chromic anhydride, lead tetraacetate, organic peracids such as peracetic acid and perbenzoic acid, inorganic peracids or salts thereof such as potassium permanganate, sodium metaperiodate, sodium perchlorate, and persulfuric acid, alcohol hydroperoxide such as tertiary-butyl-hydroperoxide and cumene hydroperoxide, halogen, selenium dioxide, ruthenium tetroxide, iodosobenzene, N-bromosuccinimide, dinitrogen pentoxide, etc.
- organic peracids such as peracetic acid and perbenzoic acid
- inorganic peracids or salts thereof such as potassium permanganate, sodium metaperiodate, sodium perchlorate, and persulfuric acid
- alcohol hydroperoxide
- the reaction temperature is suitably selected depending on the objective compounds and the oxidizing agents employed; that is, for preparing sulfoxide derivatives, the reaction is usually carried out employing, for example, sodium metaperiodate, cumene hydroperoxide, N-bromosuccinimide, etc., at room temperature (about 20 to about 30 C.) or under cooling.
- the sulfox- 1de derivatives are also obtained by a reaction employing less than an equivalent amount of a drastic oxidizing agent such as hydrogen peroxide, potassium permanganate, etc. under cooling, or, if desired, at room temperature, or at a temperature lower than 60 C., desirably lower than 40 C.
- the chloroform layer after being washed with water and dried, is subjected to evaporation under reduced pressure to remove the solvent, and the oily residue is recrystallized from ether to give 4 g. of 2,4-dichlorobenzyl methyl sulfoxide as flakes melting at 59 C. Yield: 93%.
- EXAMPLE 4 To a solution of 4 g. of 2,4-dichlorobenzyl methyl sulfide dissolved in 20 ml. of acetic acid, there is added under stirring 6 g. of 30% aqueous solution of hydrogen peroxide and the mixture solution is stirred for 4 hours at 7080 C. After cooling, there is added to the resultant solution a saturated aqueous solution of sodium sulfite to decompose excess hydrogen peroxide, and then subjected to evaporation to remove the solvent. To the residue, there is added chloroform and water and the resultant mixture is shaken thoroughly, followed by separation of the chloroform layer.
- the chloroform layer after being Washed with water and dried, is subjected to evaporation to remove the solvent, and the resultant residue is recrystallized from ethanol to give 4.3 g. of 2,4-dichlorobenzyl methyl sulfone as needles melting at 112 C. Yield: 93%.
- the chloroform layer after being washed with water and dried, is subjected to evaporation to remove the solvent, and to the oily residue there is added petroleum ether to precipitate the crystals.
- the crystals are recrystallized from carbon tetrachloride to give 2 g. of 2-bromo-6-chlorobenzyl methyl sulfone as needles melting at 121-123 C. Yield: 80%.
- EXAMPLE 7 To 2.0 g. of 2-chloro-6-fluorobenzyl methyl sulfide dissolved in 30 ml. of acetic acid, there is added dropwise under stirring 3 g. of 30% aqueous solution of hydrogen peroxide and then the mixture is further stirred for 4 hours at 70-80 C. After cooling the reaction solution a saturated aqueous solution of sodium sulfite is added thereto to decompose excess hydrogen peroxide and the resultant solution is subjected to evaporation to remove the solvent. To the residue, there are added chloroform and water and the mixture is shaken thoroughly, followed by separation of the chloroform layer.
- the chloroform layer after being Washed with water and dried, is subjected to evaporation under reduced pressure to remove chloroform and the residue is recrystallized from carbon tetrachloride to give 1.9 g. of 2-chloro-6-fiuorobenzyl methyl sulfone meltin gat 79-81" C. Yield: 81%.
- EXAMPLE 8 To 3.8 g. of 2-chloro-6-fluorobenzyl methyl sulfide dissolved in 30 ml. of acetic acid, there is added dropwise under stirring 2 g. of 30% aqueous solution of hydrogen peroxide dissolved in 10 ml. of acetic acid and then the mixture solution is further stirred for one hour at room temperature. The resultant solution is subjected to evaporation under reduced pressure to remove the solvent. The residue is dissolved in chloroform and the resultant solution is washed with an aqueous solution of sodium hydrogencarbonate and then with a saturated aqueous solution of sodium sulfite.
- EXAMPLE 9 A mixture of 12 g. of 2,6-dichlorobenzyl bromide, 6 g. of finely-powdered sodium methanesulfinate and 100 ml. of 80% ethanol is refluxed for 8 hours. After an irritative odor is distinguished, the resultant solution is concentrated to dryness under reduced pressure. To the residue, there is added water to dissolve produced sodium bromide and sodium methanesulfinate, and water insolubles are filtered off from the resultant solution. The substance is recrystallized from ethanol to give 10.7 g. of 2,6-dichlorobenzyl methyl sulfone as plates melting at 102l03 C. Yield: 89%.
- EXAMPLE 10 A mixture of 9.7 g. of 2,4-dichlorobenzyl chloride, 6 g. of finely-powdered sodium methanesulfinate and 100 ml. of methanol is refluxed for 10 hours and the resultant solution is subjected to distillation under reduced pressure to remove methanol. To the residue, there is added water and the resultant mixture is filtered to obtain a water-insoluble solid substance. The solid substance is recrystallized from ethanol to give 10.2 g. of 2,4-dichlorobenzyl methyl sulfone as crystals melting at 112 C. Yield: 85%.
- EXAMPLE 12 A mixture of 2.8 g. of 2-chloro-6-bromobenzyl bromide, 1.1 g. of sodium methanesulfinate and 50 ml. of methanol is refluxed for 3 hours. The reaction mixtureis subjected to distillation under reduced pressure to remove methanol and the residue is mixed thoroughly with water, followed by filtration. After drying, the water-insoluble solid is recrystallized from carbon tetrachloride to give 2.4 g. of 2-chloro-6-bromobenzyl methyl sulfone melting at l21-l23 C. Yield:
- EXAMPLE 13 A mixture of 5.6 g. of 2-chloro-6-fiuorobenzyl bromide 27 g. of sodium methanesulfinate and 50 ml. of methanol is refluxed for hours. The resultant solution is subjected to distillation under reduced pressure to remove methanol. The residue is mixed with a small quantity of water and from the mixture, water-insoluble crystals are separated. After Washing with water and drying, the crystals are recrystallized from carbon tetrachloride to give 5 g. of 2- chloro-6-fluorobenzyl methyl sulfone melting at 79-81 C. Yield: 90%.
- the new compounds of the present invention can be administered in a variety of forms of composition, some examples of which are as follows:
- a compound as claimed in claim 2 namely, 2,6- dichlorobenzyl methyl sulfone.
- a compound as claimed in claim 2 namely, 2- chloro-6-fiuorobenzyl methyl sulfone.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
United States Patent O flice Patented Sept. 2, 1969 ABSTRACT OF THE DISCLOSURE 2,4- or 2,6-dihalobenzyl methyl sulfoxides and the corresponding sulfones of the formula @om-sm-orn X wherein X is Cl, Br or F in the 6-position or C1 in the 4-position and n=1 or 2 are effective anti-inflammatory agents.
The present invention relates to novel compounds useful as anti-inflammatory agents. More concretely stated, the invention concerns as series of 2,4- and 2,6-dihalo-benzy1 methyl sulfoxides and a series of the corresponding 2,4- 30 and 2,6-dihalo-benzyl methyl sulfones.
Inflammation in its various manifestations represents one of the serious problems in the clinical field. Although it is known that many diseases may be engendered thereby,
clinical physicians have often encountered difficulties in 35 eliminating inflammation in the therapy of various diseases. Prompt removal of inflammation or prevention of the occurrence thereof is very important for shortening the term of disease and for removing pain as quickly as possible. Many attempts have been made to provide anti- 40 inflammatory agents suitable for these purposes.
Present anti-inflammatory agents can be divided into two groups; (a) steroidal anti-inflammatory agents, re.
adrenocortical hormones such as prednisolone, triamcinoline, hydrocortisone, dexamethasone, or the like, and (b) non-steroidal anti-inflammatory agents which consist mainly of pyrazolidine derivatives such as phenylbutazone, oxyphenbutazone, 1,4-diphenyl-3,S-dioxopyrazolidine, aminopyrine, and the like, salicyclic acid derivatives such as acetyl salicyclic acid, and the like, andmore recentlydimethylsulfoxide.
However, those of the former group provoke hypofunction of the anterior pituitary gland and adrenal cortex when they are used for a slightly prolonged period. Once such phenomena occur to a patient, administration of such steroidal anti-inflammatory agents must continue throughout his life. On the other hand, those of the second group 5 are often accompanied by undesirable side effect on elements of the digestive system such as stomach, intestinal canal, etc. and often disturb the normal functions of kidney, liver, heart, etc. Therefore, both groups of anti-inflammatory agents necessitate careful administration to patients, especially to those whole illness involves any hormonic and metabolic mechanism and/ or functions of their viscera such as stomach, intestinal canal, kidney, liver, heart, etc. Accordingly, debut of an anti-inflammatory agent which is safely administrable to patients in a wide field of inflammatory conditions has long been a desideratum in the art.
According to the present invention, a series of novel nonsteroidal 2,4- and 2,6-dihalo-benzyl methyl sulfoxides and the corresponding sulfones of the formula @om-sm-om wherein X stands for Cl, Br or F attached to the 6-position, or Cl attached to the 4-position, and n is 1 or 2, having an effective anti-inflammatory activtity, is provided.
These novel compounds of Formula I show an effective anti-inflammatory activity with a lower toxicity than hitherto-known non-steroidal anti-inflammatory agents. Detailed animal experimental data on the said anti-inflammatory action are shown in the following table:
Anti-inflanunatory action 1 Dose, Inhibition, Probability, LDEO See footnotes at end of table.
Anti-inflammatory action 1 Dose, Inhibition, Probability, LD Compound mg./k. percent percent mgJkg.
Cl Q-omso OH; 50 50. 0. 01 250-500 I Q-omso CH; 32.8 0. 05 250-500 01 Q-omso CH3 12. 5 40. 6 0. 01 250 Acetyl salicylic acid 200 48. 9 0. 01 600 Phenylbutazone 100 46. 3 0. 01 340 CH3 G1 CHSO CH 200 7. 6 1,000
o1-oms02orn 300 20.1 0. 05 1, 000
2 The median lethal dose (LD;,0) was measured by intraperitoneal administration in m ce.
3 Not significant.
Furthermore, compounds (I) show no such side effects as often accompany steroidal compounds, and show far less side efiects than hitherto-known non-steroidal antiinflammatory agents.
The present compounds (I) also exhibit an analgetic action, and an inhibitory effect against pulmonary (lung) affections due to influenza virus, etc.
It is one object of the present invention to provide such valuable and novel 2,4- and 2,6-dihalo-benzyl methyl sulfoxides and sulfones (I) which are useful as anti-inflammatory agents.
A further object is to provide new pharmaceutical compositions containing a compound or compounds (I).
Other objects of the present invention and advantageous features thereof will become apparent as the description proceeds.
These compounds (I) can be prepared by, for example, subjecting the compounds of the formula I @om-s-om wherein X has the same meaning as above, to oxidation.
For the purposes of the oxidation, such conventional oxidizing agents may be employed as, for example, hydrogen peroxide, manganese dioxide, nitric acid, chromic acid, chromic anhydride, lead tetraacetate, organic peracids such as peracetic acid and perbenzoic acid, inorganic peracids or salts thereof such as potassium permanganate, sodium metaperiodate, sodium perchlorate, and persulfuric acid, alcohol hydroperoxide such as tertiary-butyl-hydroperoxide and cumene hydroperoxide, halogen, selenium dioxide, ruthenium tetroxide, iodosobenzene, N-bromosuccinimide, dinitrogen pentoxide, etc.
Though the presence of a solvent is not essential, particularly in the case where a liquid oxidizing agent is employed, the reaction of this invention is usually carried out in a suitable solvent, for the purpose of accelerating the reaction or of avoiding side-reactions. The solvent is exemplified as water, alcohols (e.g. methanol, ethanol), organic acids (e.g. acetic acid, butyric acid, formic acid), halogenated hydrocarbons (e.g. chloroform, carbon tetrachloride, ethylene chloride), hydrocarbons (e.g. benzene, toluene, hexane), ethers (e.g. tetrahydrofuran, dioxane), ketones (e.g. acetone, methylethylketone), or the like.
The reaction may proceed under alkaline, neutral or acid conditions in said solvent, preferably pH varying with the objective compound or oxidizing agent employed, for example, when hydrogen peroxide or peracids are employed as the oxidizing agents, weakly alkaline conditions are desirable for preparing sulfoxide derivatives, and weakly acid conditions are desirable for preparing sulfone derivatives.
The reaction temperature is suitably selected depending on the objective compounds and the oxidizing agents employed; that is, for preparing sulfoxide derivatives, the reaction is usually carried out employing, for example, sodium metaperiodate, cumene hydroperoxide, N-bromosuccinimide, etc., at room temperature (about 20 to about 30 C.) or under cooling. Alternatively, the sulfox- 1de derivatives are also obtained by a reaction employing less than an equivalent amount of a drastic oxidizing agent such as hydrogen peroxide, potassium permanganate, etc. under cooling, or, if desired, at room temperature, or at a temperature lower than 60 C., desirably lower than 40 C. On the other hand, for preparing sulfone derivatives, the reaction is usually carried out at room temperature or under heating; however, the reaction may also be carried out under cooling. In brief, the sulfoxide derivatives can be prepared by employing a mild oxidizing agent or by employing a drastic oxidizing agent under mild conditions, while the sulfone derivatives can be prepared by employing more than two equivalents of an oxidizing agent and under more drastic conditions than those employed for preparing the sulfoxide derivatives. A mixture of sulfoxides and sulfones is sometimes obtained depending upon the reaction conditions, and the mixture is useful as it is for an anti-inflammatory agent, etc.; therefore it is not always necessary to separate the mixture into each component.
Among the present compounds, the 2,4- or 2,6-dihalobenzyl methyl sulfones (I) can also be prepared by allowing the compound of the formula to react With the compound of the formula CH Y wherein X has the same significance as above, and one of the Y and Y is halogen (e.g. Cl, Br, etc.) or tosyloxy and the other is the SO -alkali metal (e.g. SO -sodium, SO -potassium, SO -ammonium, etc.) radical. In the reaction the halogen attached to the aromatic ring does not react with the compounds having an SO -alkali metal radical. The present reaction is usually carried out in a suitable solvent such as water, alcohol (e.g. methanol, ethanol), aromatic hydrocarbon (e.g. benzene, toluene, xylene), ether (e.g. dioxane), or the like, or a mixture thereof. The reaction is accelerated by heating, and completed usually in 3 to hours.
The sulfoxides and sulfones (I) are useful as anti-inflammatory agents and are generally administered in the form of capsule, syrup, oil, injection, ointment, tablet, etc., i.e. orally, parenterally or topically. Pharmaceutical compositions containing one or more of the dialkyl-sulfoxides or sulfones (I) can be prepared according to any per se conventional means for the preparation of capsules, syrups, oils, injections, etc.
In the various aforesaid administrational forms, the active ingredient (I) may be present in a minor proportion with the carrier constituting the major proportion. However, the reverse relationship may also exist, so that a minor proportion of carrier is employed in association with a major proportion of active ingredient. Examples of administrational compositions are hereinafter exemplified.
The compounds (I) are also helpful in relieving disorders such as edema, and in alleviating pain and fever in acute or chronic rheumatoid arthritis and other musculoskeletal disorders.
A typical effective daily dose of the sulfoxides and sulfones (I) for an adult is usually about 100 mg. to 3 g. desirably 0.5 to l g., although an increased or reduced daily dose is also effective depending on the severity of the inflammation being treated, the indicated dose being especially suitable against inflammation caused e.g. by rheumatic fever.
It is to be understood that the following examples are solely for the purpose of illustration and not to be construed as limitations of this invention, and that minor variations may be resorted to without departing from the spirit and scope of this invention. In the said examples, g, ml, and mg. stand for gram(s), milliliter(s) and milligram(s), respectively. Temperatures are all uncorrected, and percentages are all on the weight basis.
EXAMPLE 1 To 6.2 g. of 2,6-dichlorobenzyl methyl sulfide dissolved in 20 ml. of acetic acid, there is stirred in dropwise in 10 minutes 3.6 g. of a 30% aqueous solution of hydrogen peroxide dissolved in 20 ml. of acetic acid, then the mixture solution is stirred for further 10 minutes, followed by further stirring for one hour at room temperature. To the solution is added a saturated aqueous solution of sodium sulfite to decompose excess hydrogen peroxide and then the resultant solution is subjected to evaporation under reduced pressure to remove the solvent. To the oily residue, there is added water, and the mixture is agitated to precipitate crystals. The crystals are washed with water, and then recrystallized from carbon tetrachloride to obtain 6.3 g. of 2,6-dichlorobenzyl methyl sulfoxide as needles melting at 1l6ll8 C. Yield: 94%.
6 EXAMPLE 2 To a solution of 3.1 g. of 2,6-dichlorobenzyl methyl sulfide in 20 ml. of acetic acid, there is added under stirring 318 g. of 30% aqueous hydrogen peroxide, and the mixture solution is stirred for 4 hours at 70-80 C. After cooling, there is added to the resultant solution a. saturated aqueous solution of sodium sulfite to decompose excess hydrogen peroxide and subjected to evaporation under reduced pressure to remove the solvent. To the oily residue, there are added water and chloroform, and the cholorform layer is separated. The chloroform layer, after being washed with water and dried, is subjected to evaporation under reduced pressure to leave solid residue, which is recrystallized from ethanol to give 3.3 g. of 2,6-dichlorobenzyl methyl sulfone as flakes melting at 102-103 C. Yield: 92%.
EXAMPLE 3 To 4 g. of 2,4-dichlorobenzyl methyl sulfide dissolved in 20 ml. of acetic acid, there is added dropwise in 30 minutes under stirring 2 g. of 30% aqueous solution of hydrogen peroxide dissolved in 10 ml. of acetic acid under ice-cooling and then the mixture solution is further stirred for one hour at room temperature. To the reaction solution, there is added a saturated aqueous solution of sodium sulfite to decompose excess hydrogen peroxide and then the resultant solution is subjected to evaporation under reduced pressure to remove the solvent. To the desidue, there is added chloroform and water, and the mixture is shaken thoroughly, followed by separation of chloroform layer. The chloroform layer, after being washed with water and dried, is subjected to evaporation under reduced pressure to remove the solvent, and the oily residue is recrystallized from ether to give 4 g. of 2,4-dichlorobenzyl methyl sulfoxide as flakes melting at 59 C. Yield: 93%.
EXAMPLE 4 To a solution of 4 g. of 2,4-dichlorobenzyl methyl sulfide dissolved in 20 ml. of acetic acid, there is added under stirring 6 g. of 30% aqueous solution of hydrogen peroxide and the mixture solution is stirred for 4 hours at 7080 C. After cooling, there is added to the resultant solution a saturated aqueous solution of sodium sulfite to decompose excess hydrogen peroxide, and then subjected to evaporation to remove the solvent. To the residue, there is added chloroform and water and the resultant mixture is shaken thoroughly, followed by separation of the chloroform layer. The chloroform layer, after being Washed with water and dried, is subjected to evaporation to remove the solvent, and the resultant residue is recrystallized from ethanol to give 4.3 g. of 2,4-dichlorobenzyl methyl sulfone as needles melting at 112 C. Yield: 93%.
EXAMPLE 5 To 2.2 g. of 2-bromo-6-chlorobenzyl methyl sulfide dissolved in 15 ml. of acetic acid, there is added dropwise under stirring 1.1 g. of 30% aqueous solution of hydrogen peroxide dissolved in 10 ml. of acetic acid, and then the mixture solution is further stirred for one hour at room temperature. To the reaction solution, there is added a saturated aqueous solution of sodium sulfite to decompose excess hydrogen peroxide and then the resultant solution is subjected to evaporation under reduced pressure to remove the solvent. To the oily residue, there is added water and the mixture is agitated to precipitate crystals. The crystals, after being washed with water, are recrystallized from carbon tetrachloride to give 2.3 g. of 2-bromo- 6-chlorobenzyl methyl sulfoxide as prisms melting at 122- 124 C. Yield: 97%.
EXAMPLE 6 To a solution of 2.2 g. of 2-bromo-6-chlorobenzyl methyl sulfide in 30 ml. of acetic acid, there is added dropwise 2.4 g. of 30% aqueous hydrogen peroxide and the mixture is stirred for 4 hours at 70-80" C. After cooling the reaction solution a saturated aqueous solution of sodium sulfite is added thereto to decompose excess hydrogen peroxide and then the resultant solution is subjected to evaporation under reduced pressure to remove the solvent. To the oily residue, there is added chloroform and water, and the mixture is shaken thoroughly, followed by separation of the chloroform layer. The chloroform layer, after being washed with water and dried, is subjected to evaporation to remove the solvent, and to the oily residue there is added petroleum ether to precipitate the crystals. The crystals are recrystallized from carbon tetrachloride to give 2 g. of 2-bromo-6-chlorobenzyl methyl sulfone as needles melting at 121-123 C. Yield: 80%.
EXAMPLE 7 To 2.0 g. of 2-chloro-6-fluorobenzyl methyl sulfide dissolved in 30 ml. of acetic acid, there is added dropwise under stirring 3 g. of 30% aqueous solution of hydrogen peroxide and then the mixture is further stirred for 4 hours at 70-80 C. After cooling the reaction solution a saturated aqueous solution of sodium sulfite is added thereto to decompose excess hydrogen peroxide and the resultant solution is subjected to evaporation to remove the solvent. To the residue, there are added chloroform and water and the mixture is shaken thoroughly, followed by separation of the chloroform layer. The chloroform layer, after being Washed with water and dried, is subjected to evaporation under reduced pressure to remove chloroform and the residue is recrystallized from carbon tetrachloride to give 1.9 g. of 2-chloro-6-fiuorobenzyl methyl sulfone meltin gat 79-81" C. Yield: 81%.
EXAMPLE 8 To 3.8 g. of 2-chloro-6-fluorobenzyl methyl sulfide dissolved in 30 ml. of acetic acid, there is added dropwise under stirring 2 g. of 30% aqueous solution of hydrogen peroxide dissolved in 10 ml. of acetic acid and then the mixture solution is further stirred for one hour at room temperature. The resultant solution is subjected to evaporation under reduced pressure to remove the solvent. The residue is dissolved in chloroform and the resultant solution is washed with an aqueous solution of sodium hydrogencarbonate and then with a saturated aqueous solution of sodium sulfite. After drying, the solution is subjected to evaporation to remove chloroform, and to the resultant residue, there is added petroleum ether -to yield crystals. The crystals are recrystallized from ligroin to give 3.4 g. of 2-chloro-6-fluorobenzyl methyl sulfoxide as flakes melting at 8991 C. Yield: 83%.
EXAMPLE 9 A mixture of 12 g. of 2,6-dichlorobenzyl bromide, 6 g. of finely-powdered sodium methanesulfinate and 100 ml. of 80% ethanol is refluxed for 8 hours. After an irritative odor is distinguished, the resultant solution is concentrated to dryness under reduced pressure. To the residue, there is added water to dissolve produced sodium bromide and sodium methanesulfinate, and water insolubles are filtered off from the resultant solution. The substance is recrystallized from ethanol to give 10.7 g. of 2,6-dichlorobenzyl methyl sulfone as plates melting at 102l03 C. Yield: 89%.
EXAMPLE 10 A mixture of 9.7 g. of 2,4-dichlorobenzyl chloride, 6 g. of finely-powdered sodium methanesulfinate and 100 ml. of methanol is refluxed for 10 hours and the resultant solution is subjected to distillation under reduced pressure to remove methanol. To the residue, there is added water and the resultant mixture is filtered to obtain a water-insoluble solid substance. The solid substance is recrystallized from ethanol to give 10.2 g. of 2,4-dichlorobenzyl methyl sulfone as crystals melting at 112 C. Yield: 85%.
8 EXAMPLE 11 9.7 g. of 2,6-dichlorobenzyl chloride and 4.9 g. of ammonium methanesulfinate are reacted in the same manner as in Example 10, to give 10.2 g. of 2,6-dichlorobenzyl methyl sulfone. Wield: 85%.
EXAMPLE 12 A mixture of 2.8 g. of 2-chloro-6-bromobenzyl bromide, 1.1 g. of sodium methanesulfinate and 50 ml. of methanol is refluxed for 3 hours. The reaction mixtureis subjected to distillation under reduced pressure to remove methanol and the residue is mixed thoroughly with water, followed by filtration. After drying, the water-insoluble solid is recrystallized from carbon tetrachloride to give 2.4 g. of 2-chloro-6-bromobenzyl methyl sulfone melting at l21-l23 C. Yield:
EXAMPLE 13 A mixture of 5.6 g. of 2-chloro-6-fiuorobenzyl bromide 27 g. of sodium methanesulfinate and 50 ml. of methanol is refluxed for hours. The resultant solution is subjected to distillation under reduced pressure to remove methanol. The residue is mixed with a small quantity of water and from the mixture, water-insoluble crystals are separated. After Washing with water and drying, the crystals are recrystallized from carbon tetrachloride to give 5 g. of 2- chloro-6-fluorobenzyl methyl sulfone melting at 79-81 C. Yield: 90%.
EXAMPLE l4 2,6-dichlorobenzyl methyl sulfide (4.1 g.) is added little by little with stirring to a solution of sodium metaperiodide (4.3 g.) in 80 ml. of water while keeping the reaction temperature not higher than 5 C. with ice. After agitating for one hour, the reaction solution is saturated with sodium chloride. So-saturated solution is shaken with 200 ml. of chloroform. The chloroform layer is separated and then dried, followed by concentration under reduced pressure to leave oily residue, from which 3.2 g. of 2,6-dichlorobenzyl methyl sulfoxide is obtained by recrystallization from carbon tetrachloride, as needless melting at 1l6-118 C.
EXAMPLE 15 A chloroform solution (30 ml.) containing 0.0535 g. of perbenzoic acid per ml. is added gradually to a solution of 2.0 g. of 2,4-dichlorobenzyl methyl sulfide in 30 ml. of chloroform with stirring, under cooling with ice to keep the reaction temperature lower than 5 C.
The reaction solution is agitated for one hour, then 10 ml. of 0.1 normal aqueous sodium thiosulfate is added thereto, followed by vigorous stirring. The chloroform layer is washed with 10% aqueous potassium carbonate solution and then with a saturated aqueous solution of sodium chloride, followed by drying. The solvent is then distilled off to leave 1.8 g. of 2,4-dichlorobenzyl methyl sulfoxide as an oily substance, which is recrystallized from other to give flakes melting at 59 C.
EXAMPLE 16 6 ml. of a toluene solution containing 0.76 g. of cumene hydroperoxide per ml. is added to a solution of 1.9 g. of 2-chloro-6-fiuorobenzyl methyl sulfide in 20 ml. of chloroform with stirring under cooling with ice. After agitating for one hour, the reaction solution is left for 3 days at room temperature.
After the solvent is distilled off under reduced pressure, the residue is shaken with a mixture of water and chloroform. The chloroform layer, after being washed with water and dried, is subjected to distillation to remove the solvent, and the residue is recrystallized from ligroin to give 1.5 g. of 2-chloro-6-fluorobenzyl methyl sulfoxide as flakes melting at 8991 C.
As indicated hereinbefore, the new compounds of the present invention can be administered in a variety of forms of composition, some examples of which are as follows:
Composition 1 Milligrams per tablet 2,6-dichlorobenzyl methyl sulfoxide 100.0 Milk sugar 200.0 Starch 78.0 Starch paste (dried) 20.0 Magnesium stearate 2.0
Milligrams 2,6-dichlorobenzyl methyl sulfoxide 100 Lactose 700 Starch 200 All ingredients are thoroughly mixed, the resultant admixture being a composition useful as an oral powder.
Composition 3 2,6-dichlorobenzyl methyl sulfoxide is intimately admixed with white petrolatum and the resultant ointment dispensed via a collapsible tube. The amount of petrolatum is such that a one-inch expressed amount of ointment contains to 20 milligrams for topical application.
Composition 4 As hereinbefore indicated, the active ingredient may constitute a major proportion of the administered composition. Thus a composition may comprise, for example.
Milligrams 2,6-dichlorobenzyl methyl sulfone 270 Lactose 25 Corn meal 100 Magnesium stearate 5 -om-so.om
wherein X is a member selected from the group consisting of Cl, Br and F attached to the 6-position, or Cl attached to the 4-position, and n is 1 or 2.
2. A compound as claimed in claim 1, wherein n is 2.
3. A compound as claimed in claim 2, namely, 2,6- dichlorobenzyl methyl sulfone.
4. A compound as claimed in claim 2, namely, 2,4- dichlo-robenzyl methyl sulfone.
5. A compound as claimed in claim 2, namely, 2- chloro-6-fiuorobenzyl methyl sulfone.
6. A compound as claimed in claim 2, namely, 2- chloro-6-bromobenzyl methyl sulfone.
7. A compound as claimed in claim 1, wherein n is 1.
8. A compound as claimed in claim 7, namely, 2,6- dichlorobenzyl methyl sulfoxide.
9. A compound as claimed in claim 7, namely, 2- chlo ro-6-bromobenzyl methyl sulfoxide.
10. A compound as claimed in claim 7, namely, 2- chloro-6-bromobenzyl methyl sulfoxide.
11. A compound as claimed in claim 7, namely, 2- chloro-6-fluorobenzyl methyl sulfoxide.
References Cited Orda et al.: Chem. Abstracts, vol. 63 (1965), pp. 1684-85.
Bordwellet al.: J.A.C.S.,vol. 77 (1955), pp. 572-577.
Lewis et al.: J.A.C.S., vol. 73 (1951), pp. 2109-2113.
CHARLES B. PARKER, Primary Examiner D. R. PHILLIPS, Assistant Examiner U.S. Cl. X.R. 424337 33 7 UNITED ST-ATES PATENT OFFICE t CERTIFICATE OF CORRECTION Patent 3.461044 r Dated September 2 1969 vent ')HIROSHI HIRANO, KATSUTADA MASUDA, KIYOHISA KAWAI and NOBORU SHIMAHARA' It is ce rtified that error appears in the above-identified patent and that said Letters Patent are herby cbrrected as shown below:
On column 1, line 9, before Match 8', 1966, insert February 28, 1966-, 41/1-2443 V Signed and sealed this 22nd day of February 1972.
(SEAL) Attest:
ROBERT GOTTSCHALK E :1 .FLETCHER JR.
RD M Commissioner of Pa Att sting Officer
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1443766 | 1966-03-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US3465044A true US3465044A (en) | 1969-09-02 |
Family
ID=11860979
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US619167A Expired - Lifetime US3465044A (en) | 1966-03-08 | 1967-02-28 | 2,4- and 2,6-dihalobenzyl methyl sulfoxides and sulfones |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US3465044A (en) |
| DE (1) | DE1291740B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3615745A (en) * | 1969-03-10 | 1971-10-26 | Abbott Lab | Antimicrobial coatings and method using diiodomethyl sulfones |
| US4064178A (en) * | 1975-05-19 | 1977-12-20 | Ppg Industries, Inc. | Bis(4-chlorophenyl)methyl methyl sulfoxide |
| US4103031A (en) * | 1976-06-30 | 1978-07-25 | Ppg Industries, Inc. | Control of plant pests with bis(4-chlorophenyl)methyl methyl sulfoxide |
| US4117168A (en) * | 1976-07-07 | 1978-09-26 | Ppg Industries, Inc. | Antifungal di(aryl)methyl alkyl sulfones |
| US4628087A (en) * | 1983-05-13 | 1986-12-09 | Zambon S.P.A. | Process for the preparation of pharmacologically active compounds containing a sulfoxide group |
-
1967
- 1967-02-28 DE DET35301A patent/DE1291740B/en active Pending
- 1967-02-28 US US619167A patent/US3465044A/en not_active Expired - Lifetime
Non-Patent Citations (1)
| Title |
|---|
| None * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3615745A (en) * | 1969-03-10 | 1971-10-26 | Abbott Lab | Antimicrobial coatings and method using diiodomethyl sulfones |
| US4064178A (en) * | 1975-05-19 | 1977-12-20 | Ppg Industries, Inc. | Bis(4-chlorophenyl)methyl methyl sulfoxide |
| US4067909A (en) * | 1975-05-19 | 1978-01-10 | Ppg Industries, Inc. | Novel di(aryl)methyl alkyl sulfones |
| US4103031A (en) * | 1976-06-30 | 1978-07-25 | Ppg Industries, Inc. | Control of plant pests with bis(4-chlorophenyl)methyl methyl sulfoxide |
| US4117168A (en) * | 1976-07-07 | 1978-09-26 | Ppg Industries, Inc. | Antifungal di(aryl)methyl alkyl sulfones |
| US4628087A (en) * | 1983-05-13 | 1986-12-09 | Zambon S.P.A. | Process for the preparation of pharmacologically active compounds containing a sulfoxide group |
Also Published As
| Publication number | Publication date |
|---|---|
| DE1291740B (en) | 1969-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5925631A (en) | Alkylated styrenes as prodrugs to COX-2 inhibitors | |
| PL94252B1 (en) | 1-Oxo-2,2-disubstituted-5-indanyloxy(or thio)alkanoic acids[US3984465A] | |
| US3465044A (en) | 2,4- and 2,6-dihalobenzyl methyl sulfoxides and sulfones | |
| US3652665A (en) | Halo-phenoxy salicylic acids | |
| JP2000505421A (en) | Alkylated styrene as prodrug of COX-2 inhibitor | |
| US3668223A (en) | 2-oxo-3-benzoxepins | |
| US3812109A (en) | Substituted indenyl glucoronide esters | |
| US3255242A (en) | (alpha-alkylideneacyl)naphthyloxy monocarboxylic acids | |
| Meinwald | The Acid-catalyzed Rearrangement of Cinenic Acid1 | |
| EP0096890A2 (en) | Oxazoleacetic acid derivatives, process for their production and compositions containing said derivatives | |
| US4091097A (en) | Treatment of elevated histamine and uric acid levels | |
| US3210413A (en) | Antihypercholesterolemic agents | |
| US4569945A (en) | Diarylindane-1,3-diones, their preparation and use | |
| US3455956A (en) | Dialkyl-sulfoxides and dialkyl-sulfones | |
| US4036983A (en) | Ferrocene compounds and pharmaceutical composition for use in treatment of iron deficiency in an animal | |
| US3488424A (en) | Derivatives of thiachromane as diuretics | |
| US4123544A (en) | Acetylsalicylic acid derivatives | |
| US3506658A (en) | 2-(10-methyl-2-phenoxazinyl)propionic acid | |
| US3870792A (en) | Certain dihydrophthalizines for treating hemorrhage and thrombosis | |
| US3674875A (en) | The treatment of inflammation | |
| US3481972A (en) | Substituted hydroxyethyl acid hydrazides | |
| CH659251A5 (en) | DICHLORIN DERIVATIVES OF 16ALPHA-METHYL PREGNANE, THEIR PREPARATION AND THE THERAPEUTIC COMPOSITIONS CONTAINING THEM. | |
| EP0020230B1 (en) | P-biphenyl-4-methyl-2-butenoic acids, process for their preparation, pharmaceutical compositions containing them and their use | |
| US4024253A (en) | Treatment of elevated histamine and uric acid levels | |
| US3883660A (en) | Treatment of pain, fever or inflammation with 5-fluoro-2-methyl-1-cp-methylsulfinyl-benzylidene)-3-indenylacetaldehyde |